person · Reporting owner

Adelman Michael

Disclosed activity across 1 company

Tapewire entity: 150451
SEC CIK: 0001749435

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aptevo Therapeutics Inc.APVO · Entity 8337	SVP, Commercial Operations	February 18, 2020	March 19, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aptevo Therapeutics Inc.

Report date February 18, 2020 · Filed March 19, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2030-02-17	Direct	134,800	Reported balance After 2020-02-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-18 · Grant · Acquired 134,800 · Balance 134,800 F1: The option vests in three approximately equal annual installments beginning on February 17, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in three approximately equal annual installments beginning on February 17, 2021.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 18, 2020 Filed Mar 19, 2020 22:33 UTC	Aptevo Therapeutics Inc. APVO · Entity 8337	GrantStock Option (right to buy) · Derivative	134,800	$0.00 Strike: $0.50	$0.00	Disclosure SEC source: 0001019056-20-000239 · adelman.xml · derivative · entry 1 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,800 Underlying: Common Stock · 134,800 shares Expires 2030-02-17 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 17, 2021. Read SEC document
November 01, 2019 Filed Nov 6, 2019 01:50 UTC	Aptevo Therapeutics Inc. APVO · Entity 8337	GrantStock Option (right to buy) · Derivative	114,247	$0.00 Strike: $0.58	$0.00	Disclosure SEC source: 0001019056-19-000610 · adelman.xml · derivative · entry 1 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,247 Underlying: Common Stock · 114,247 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document
March 01, 2019 Filed Mar 5, 2019 02:03 UTC	Aptevo Therapeutics Inc. APVO · Entity 8337	Exercise / conversionRestricted Stock Unit · Derivative	7,318	$0.00	$0.00	Disclosure SEC source: 0001019056-19-000174 · adelman.xml · derivative · entry 4 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 1, 2016 the reporting person was granted 21,958 restricted stock units. 7,320 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. F3 · derivative.expiration_date: On March 1, 2016 the reporting person was granted 21,958 restricted stock units. 7,320 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. Read SEC document
March 01, 2019 Filed Mar 5, 2019 02:03 UTC	Aptevo Therapeutics Inc. APVO · Entity 8337	Tax withholdingCommon Stock	2,395	$1.57	$3,760.15	Disclosure SEC source: 0001019056-19-000174 · adelman.xml · nonDerivative · entry 2 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,426 Read SEC document
March 01, 2019 Filed Mar 5, 2019 02:03 UTC	Aptevo Therapeutics Inc. APVO · Entity 8337	Exercise / conversionCommon Stock	7,318	Not disclosed	Not disclosed	Disclosure SEC source: 0001019056-19-000174 · adelman.xml · nonDerivative · entry 1 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
February 28, 2019 Filed Mar 5, 2019 02:03 UTC	Aptevo Therapeutics Inc. APVO · Entity 8337	GrantStock Option (right to buy) · Derivative	67,400	$0.00 Strike: $1.52	$0.00	Disclosure SEC source: 0001019056-19-000174 · adelman.xml · derivative · entry 3 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The options vest in three approximately equal annual installments beginning on February 28, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.